Venetoclax Combined With Intensive Chemotherapy Regimens for Patients With Relapsed/Refractory Acute Myeloid Leukemia: A Systematic Review and Single‐Arm Meta‐Analysis

Venetoclax combined with intensive chemotherapy demonstrates meaningful antileukemic activity in R/R AML, with an expected toxicity profile. Prospective trials are warranted to define its role relative to standard salvage therapies.